Bank of New York Mellon
MGX icon

Bank of New York Mellon’s Metagenomi Therapeutics MGX Stock Holding History

Bank of New York Mellon’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,387
Closed -$68.5K – 4290
2025
Q1 		$68.5K Buy
50,387
+14,296
+40% +$34.1K ﹤0.01% 4034
2024
Q4 		$130K Buy
+36,091
New +$87.1K ﹤0.01% 4008

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon's MGX Position: Q2 2025 in Review

Bank of New York Mellon sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 50,387 shares — an estimated $68.5K sold.

Bank of New York Mellon first reported a position in MGX in Q4 2024 and held it in 2 quarters. The position peaked at $130K in Q4 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

  • Bank of New York Mellon reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bank of New York Mellon sold 50,387 Metagenomi Therapeutics shares in Q2 2025, an estimated $68.5K.
  • Bank of New York Mellon first reported a position in Metagenomi Therapeutics in Q4 2024 and held it in 2 quarters.
  • Bank of New York Mellon's Metagenomi Therapeutics position peaked at $130K in Q4 2024.
  • 69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.